Table 1.

Reported Lab Values for Available ADT Options

Generation	Drug (Reference)	Proportion of patients
		T ≤ 50 ng/dL	T ≤ 20 ng/dL	Nadir T ≤ 10 ng/dL	No T Escape > 50 ng/dL	PSA decline >90% or to <4 ng/mL
1	Bicalutamide [121]					39
	Flutamide [122, 123]					13−40
	Nilutamide [124]					n/d
	Cyproterone acetate [125, 126]					4−70
2	SC-leuprolide acetate [26, 32, 38]	94−99	90−96	97	98−100	91−95
	IM-leuprolide acetate [25, 33, 127]	93−95	66−79	n/d	91−98	51−87
	Triptorelin [27, 31, 35, 128, 129]	93−98	25−79	n/d	93−99	81
	Goserelin [28, 36, 130]	65−91	55	n/d	91	n/d
	Degarelix [43, 45, 46, 89]	99−100	63	n/d	97−98	69−95
	Relugolix [64]	n/d	n/d	n/d	n/d	n/d
3	Abiraterone [131, 132]	n/d	n/d	n/d	n/d	19
	Enzalutamide [59, 60]					25−47
	Apalutamide [133]					42−43
	Darolutamide [134]					30

Gray cells: Not relevant as mechanism does not affect serum testosterone

Data should not be directly compared, as numerous sources, different doses, and time points are used

n/d no data